Roche Unit Nets $775M Deal In AstraZeneca IP Row
A month after AstraZeneca's Alexion Pharmaceuticals settled claims that its antibody product Ultomiris infringed patents held by Roche-owned rival Chugai Pharmaceutical Co. Ltd., Chugai's attorneys said Thursday the settlement netted their...To view the full article, register now.
Already a subscriber? Click here to view full article